Uncategorized

The FDA needs a patient-first vision—and adcomms with patients at the table

Published

on

FDA’s rare disease decisions are strongest when the patient community has a voice in advisory committee decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version